Specific alterations (deletions, point mutations, or loss of heterozygosity) in the essential components of the MHC class I, such as beta-2-microglobulin, are found more frequently in patients with melanoma unresponsive to anti-PD-1 or anti-CTLA4 treatment [22]. This evidence concerns the gene CTLA4 and melanoma.